FDA updates PAH label with trial data - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA updates PAH label with trial data

In adults diagnosed with pulmonary arterial hypertension within the previous year, adding sotatercept to background therapy reduced the risk of clinical worsening events by 76% compared with placebo.

  • By

  • Kathryn Wighton

  • September 22, 2026

  • 3 min

Share

Original Source(s)

FDA updates PAH label with trial data

  • by Kathryn Wighton

  • September 22, 2026

Related Content

The drugs and devices have been on the market for years. But FDA-ordered studies still aren’t done.

“Doctors rely on this evidence, patients rely on this evidence, and if that evidence is not there, it’s going to lead to a lot of uncertainty."

Do out-of-pocket costs discourage care?

Higher medical expenses increased financial anxiety and reduced willingness to schedule recommended procedures in 3 studies, with stronger effects among financially stressed participants.

Medical Oddities: Alive, but convinced otherwise

A deadly conviction, healing vanilla, stormy lungs, and a COVID tea party await.